U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07386002) titled 'A Phase II Study of Intracerebroventricular MT027 in Recurrent or Progressive Glioblastoma' on Jan. 27.
Brief Summary: This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy.
Each participant will undergo screening, treatment (receiving MT027 at a dose of 3x10^7 cells), safety follow-up, and long-term follow-up periods.
MT027 will be given via ICV injection on Day 1 & Day 15 of the first 28-day cycle. I...